ArticleJournal of immunoassay & immunochemistry2012
Determination of PPARγ activity in adipose tissue and spleen.
Article in Journal of immunoassay & immunochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Article
- Novel Benzimidazole-Thiazolidine-2,4-dione Hybrid Compounds as Promising PPAR-γ Modulators with Antidiabetic Activity: Design, Synthesis, Molecular Docking, andCombinatorial chemistry & high throughput screening · 2026Article
- PPARγ: a key orchestrator of epidermal barrier, immune responses, and lipid metabolism in atopic dermatitis pathogenesis and therapy.Frontiers in allergy · 2026Review
- Regulation of Epigenetic Modifications in the Placenta during Preeclampsia: PPARγ Influences H3K4me3 and H3K9ac in Extravillous Trophoblast Cells.International journal of molecular sciences · 2021Article
- The importance of the nuclear positioning of the PPARG gene for its expression during porcine in vitro adipogenesis.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2019Article
- Treatment for cerebral small vessel disease: effect of relaxin on the function and structure of cerebral parenchymal arterioles during hypertension.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Peroxisome proliferator-activated receptor-gamma (PPARγ) is a nuclear transcription factor that regulates many genes and is involved in extensive biological functions. Accurately determining PPARγ activity in various tissues is important to understanding mechanisms of human physiology and pathophysiology. Thus, we evaluated a PPARγ DNA binding immunoassay using nuclear extracts of spleen and adipose tissue from rats treated with rosiglitazone (20 mg/kg in food, seven days, n = 6) or vehicle (n = 6) and compared the results to mRNA expression of PPARγ target genes--a well-established method to investigate PPARγ activity. In adipose tissue, the PPARγ immunoassay showed that rosiglitazone did not change PPARγ binding, but qPCR analysis showed that expression of two PPARγ target genes, CD36 and liver X receptor-α, were significantly increased. In spleen, the PPARγ immunoassay showed that rosiglitazone decreased PPARγ binding, but qPCR analysis showed no significant change. The different results obtained between PPARγ binding immunoassay and target gene expression suggest that PPARγ immunoassays may not be suitable when used with fresh homogenates of spleen and adipose tissue. Validation of the assay with each individual tissue is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.